RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk.

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial – The Lancet

Related: #ACC21 – [Not published yet] RCT: Among hospitalized patients with Covid-19 and elevated D-Dimer, therapeutic anticoagulation with Rivaroxaban 20 mg was not associated with improved outcomes and resulted in increased major bleeding.

Commentary on Twitter

Thanks @CMichaelGibson. Another important contribution from the Brazilian Coalition team and investigators in Brazil. Our 6th trial completed in 12 months. Go coalition!!!! https://t.co/TDUr1RukuW

— Renato D Lopes (@RenatoDLopes1) June 4, 2021